Cargando…

FGF23 and its role in X-linked hypophosphatemia-related morbidity

BACKGROUND: X-linked hypophosphatemia (XLH) is an inherited disease of phosphate metabolism in which inactivating mutations of the Phosphate Regulating Endopeptidase Homolog, X-Linked (PHEX) gene lead to local and systemic effects including impaired growth, rickets, osteomalacia, bone abnormalities,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beck-Nielsen, Signe Sparre, Mughal, Zulf, Haffner, Dieter, Nilsson, Ola, Levtchenko, Elena, Ariceta, Gema, de Lucas Collantes, Carmen, Schnabel, Dirk, Jandhyala, Ravi, Mäkitie, Outi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390548/ https://www.ncbi.nlm.nih.gov/pubmed/30808384 http://dx.doi.org/10.1186/s13023-019-1014-8

Ejemplares similares

The international X-linked hypophosphataemia (XLH) registry (NCT03193476): rationale for and description of an international, observational study
por: Padidela, Raja, et al.
Publicado: (2020)

The International X-Linked Hypophosphatemia (XLH) Registry: first interim analysis of baseline demographic, genetic and clinical data
por: Ariceta, Gema, et al.
Publicado: (2023)

Post-authorisation safety study of burosumab use in paediatric, adolescent and adult patients with X-linked hypophosphataemia: rationale and description
por: Brandi, Maria Luisa, et al.
Publicado: (2022)

Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries
por: Mughal, M. Zulf, et al.
Publicado: (2023)

FGF23, Hypophosphatemia, and Emerging Treatments
por: Imel, Erik A, et al.
Publicado: (2019)

Burosumab treatment in a child with cutaneous skeletal hypophosphatemia syndrome: A case report
por: Khadora, Manal, et al.
Publicado: (2021)

Paracrine Effects of FGF23 on the Heart
por: Leifheit-Nestler, Maren, et al.
Publicado: (2018)

Variation in the fibroblast growth factor 23 (FGF23) gene associates with serum FGF23 and bone strength in infants
por: Enlund-Cerullo, Maria, et al.
Publicado: (2023)

Antibody-Mediated Activation of FGFR1 Induces FGF23 Production and Hypophosphatemia
por: Wu, Ai-Luen, et al.
Publicado: (2013)

Severe Hypophosphatemia and Elevated FGF23 Level Following Zoledronic Acid Infusion
por: Betlachin, Anna, et al.
Publicado: (2021)

Lipocalin-2 is associated with FGF23 in WNT1 and PLS3 osteoporosis
por: Loid, Petra, et al.
Publicado: (2022)

FGF23 and Phosphate–Cardiovascular Toxins in CKD
por: Vogt, Isabel, et al.
Publicado: (2019)

Hypophosphatemia and FGF23 tumor-induced osteomalacia in two cases of metastatic breast cancer
por: Abramson, Matthew, et al.
Publicado: (2021)

Case Report: Unexplained Mild Hypophosphatemia and Very High Serum FGF23 Concentrations
por: Bosman, Ariadne, et al.
Publicado: (2023)

An Unusually Prolonged Case of FGF23-mediated Hypophosphatemia Secondary to Ferric Carboxymaltose Use
por: Arora, Ipsa, et al.
Publicado: (2023)

How FGF23 shapes multiple organs in chronic kidney disease
por: Leifheit-Nestler, Maren, et al.
Publicado: (2021)

Sharp rises in FGF23 and hypophosphatemia after intravenous iron administration do not cause myocardial damage
por: Brandenburg, Vincent, et al.
Publicado: (2020)

Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia
por: Linglart, Agnès, et al.
Publicado: (2021)

Clinical performance of a new intact FGF23 immunoassay in healthy individuals and patients with chronic hypophosphatemia
por: Kato, Hajime, et al.
Publicado: (2023)

Dental health of patients with X-linked hypophosphatemia: A controlled study
por: Larsson, Amila, et al.
Publicado: (2023)

SUN-364 Enthesophytes Are a Common Feature of FGF23-Mediated Hypophosphatemia Due to Tumor-Induced Osteomalacia
por: Gafni, Rachel Ilana, et al.
Publicado: (2020)

Murine models of HRAS-mediated cutaneous skeletal hypophosphatemia syndrome suggest bone as the FGF23 excess source
por: Ovejero, Diana, et al.
Publicado: (2023)

Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia
por: Ruppe, Mary D., et al.
Publicado: (2016)

A computationally identified compound antagonizes excess FGF-23 signaling in renal tubules and a mouse model of hypophosphatemia
por: Xiao, Zhousheng, et al.
Publicado: (2016)

Phenotypic characterization of X-linked hypophosphatemia in pediatric Spanish population
por: Rodríguez-Rubio, Enrique, et al.
Publicado: (2021)

Correction to: Phenotypic characterization of X-linked hypophosphatemia in pediatric Spanish population
por: Rodríguez-Rubio, Enrique, et al.
Publicado: (2021)

What are the benefits of the anti-FGF23 antibody burosumab on the manifestations of X-linked hypophosphatemia in adults in comparison with conventional therapy? A review
por: Lafage-Proust, Marie-Hélène
Publicado: (2022)

Diagnosis and management of X-linked hypophosphatemia in children and adolescent in the Gulf Cooperation Council countries
por: Al Juraibah, Fahad, et al.
Publicado: (2021)

Pharmacokinetics and pharmacodynamics of a human monoclonal anti‐FGF23 antibody (KRN23) in the first multiple ascending‐dose trial treating adults with X‐linked hypophosphatemia
por: Zhang, Xiaoping, et al.
Publicado: (2015)

FGF23-Mediated Activation of Local RAAS Promotes Cardiac Hypertrophy and Fibrosis
por: Böckmann, Ineke, et al.
Publicado: (2019)

Serum FGF23 levels may not be associated with serum phosphate and 1,25-dihydroxyvitamin D levels in patients with Fanconi syndrome–induced hypophosphatemia
por: Goto, Shunsuke, et al.
Publicado: (2016)

Fibroblast Growth Factor 23–Induced Hypophosphatemia in Acute Leukemia
por: Reinert, Rachel B, et al.
Publicado: (2018)

SAT-LB085 First Report of Burosumab (Anti-FGF23 Monoclonal Antibody) for Rickets Complicating HRAS-Associated Cutaneous Skeletal Hypophosphatemia Syndrome
por: Smith, Pamela, et al.
Publicado: (2019)

Long-Term Clinical Outcome and Carrier Phenotype in Autosomal Recessive Hypophosphatemia Caused by a Novel DMP1 Mutation
por: Mäkitie, Outi, et al.
Publicado: (2010)

Cardiac FGF23 expression correlates with left ventricular hypertrophy in patients with chronic kidney disease
por: Leifheit-Nestler, Maren, et al.
Publicado: (2014)

Combined treatment by burosumab and a calcimimetic can ameliorate hypophosphatemia due to excessive actions of FGF23 and PTH in adult XLH with tertiary hyperparathyroidism: A case report
por: Takashi, Yuichi, et al.
Publicado: (2022)

Phosphate and FGF-23
por: Jüppner, Harald
Publicado: (2011)

FGF23 and inflammation
por: Sharaf El Din, Usama A A, et al.
Publicado: (2017)

Concordance between the schedule for the evaluation of individual quality of life-direct weighting (SEIQoL-DW) and the EuroQoL-5D (EQ-5D) measures of quality of life outcomes in adults with X-linked hypophosphatemia
por: Jandhyala, Ravi
Publicado: (2022)

Nirogacestat and Hypophosphatemia
por: Gudsoorkar, Prakash, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c76aci2s5fpkl7ajki1kl9rp90